|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
GB201506509D0
(en)
|
2015-04-16 |
2015-06-03 |
Univ Wageningen |
Nuclease-mediated genome editing
|
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
US10648020B2
(en)
*
|
2015-06-18 |
2020-05-12 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN110382692A
(zh)
*
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US12595478B2
(en)
*
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
WO2018022634A1
(en)
*
|
2016-07-26 |
2018-02-01 |
The General Hospital Corporation |
Variants of crispr from prevotella and francisella 1 (cpf1)
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
CA3102054A1
(en)
|
2017-06-05 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
|
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019046540A1
(en)
*
|
2017-08-31 |
2019-03-07 |
New York Genome Center, Inc. |
METHODS AND COMPOSITIONS COMPRISING CRISPR-CPF1 AND APPROVED GUIDING CRISPR RNAES FOR PROGRAMMABLE GENOMIC DELETIONS
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
MX2020004063A
(es)
|
2017-10-20 |
2020-10-05 |
Hutchinson Fred Cancer Res |
Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
CN109957569B
(zh)
*
|
2017-12-22 |
2022-10-25 |
苏州齐禾生科生物科技有限公司 |
基于cpf1蛋白的碱基编辑系统和方法
|
|
EP3765616B1
(en)
|
2018-03-14 |
2023-07-19 |
Arbor Biotechnologies, Inc. |
Novel crispr dna and rna targeting enzymes and systems
|
|
PL3765615T3
(pl)
*
|
2018-03-14 |
2023-11-13 |
Arbor Biotechnologies, Inc. |
Nowe enzymy i układy crispr ukierunkowane na dna
|
|
US12522812B2
(en)
|
2018-05-16 |
2026-01-13 |
Arbor Biotechnologies, Inc. |
CRISPR-associated systems and components
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
GB201809709D0
(en)
|
2018-06-13 |
2018-08-01 |
Stichting Wageningen Res |
Polynucleotide constructs and methods of gene editing using CPF1
|
|
MX2020013461A
(es)
|
2018-06-26 |
2021-04-28 |
Broad Inst Inc |
Composiciones, sistemas y métodos de amplificación basados en la doble nicasa crispr.
|
|
CA3102163A1
(en)
|
2018-06-26 |
2020-01-02 |
Massachusetts Institute Of Technology |
Crispr effector system based amplification methods, systems, and diagnostics
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
EP3830301B1
(en)
|
2018-08-01 |
2024-05-22 |
Mammoth Biosciences, Inc. |
Programmable nuclease compositions and methods of use thereof
|
|
IL325857A
(en)
|
2018-08-08 |
2026-03-01 |
Integrated Dna Tech Inc |
Novel mutations that enhance DNA cleavage activity of ACIDAMINOCOCCUS SP. CPF1
|
|
CA3109083A1
(en)
*
|
2018-08-09 |
2020-02-13 |
G+Flas Life Sciences |
Compositions and methods for genome engineering with cas12a proteins
|
|
KR102096592B1
(ko)
*
|
2018-08-09 |
2020-04-02 |
(주)지플러스 생명과학 |
신규한 crispr 연관 단백질 및 이의 용도
|
|
WO2020037142A1
(en)
|
2018-08-17 |
2020-02-20 |
Yale University |
Compositions and methods for high-throughput activation screening to boost t cell effector function
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020092057A1
(en)
*
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
WO2020124050A1
(en)
|
2018-12-13 |
2020-06-18 |
The Broad Institute, Inc. |
Tiled assays using crispr-cas based detection
|
|
EP3931313A2
(en)
|
2019-01-04 |
2022-01-05 |
Mammoth Biosciences, Inc. |
Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
AU2020226864B2
(en)
*
|
2019-02-22 |
2023-09-28 |
Integrated Dna Technologies, Inc. |
Lachnospiraceae Bacterium ND2006 Cas12a mutant genes and polypeptides encoded by same
|
|
WO2020186231A2
(en)
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Crispr effector system based multiplex diagnostics
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN110129366B
(zh)
*
|
2019-05-24 |
2020-09-01 |
青岛农业大学 |
一种载体组合及其应用
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
EP4047087A4
(en)
*
|
2019-08-19 |
2023-08-23 |
Southern Medical University |
Construction of high-fidelity crispr/ascpf1 mutant and application thereof
|
|
US20220333208A1
(en)
|
2019-09-03 |
2022-10-20 |
The Broad Institute, Inc. |
Crispr effector system based multiplex cancer diagnostics
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
BR112022007125A2
(pt)
*
|
2019-10-17 |
2022-07-05 |
Pairwise Plants Services Inc |
Variantes de nucleases cas12a e métodos de produção e uso das mesmas
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
WO2021146641A1
(en)
|
2020-01-17 |
2021-07-22 |
The Broad Institute, Inc. |
Small type ii-d cas proteins and methods of use thereof
|
|
US12012433B1
(en)
|
2020-02-27 |
2024-06-18 |
Integrated Dna Technologies Inc. |
Expression and purification of Cas enzymes
|
|
WO2021178934A1
(en)
*
|
2020-03-06 |
2021-09-10 |
Metagenomi Ip Technologies, Llc |
Class ii, type v crispr systems
|
|
GB2617658B
(en)
*
|
2020-03-06 |
2024-04-17 |
Metagenomi Inc |
Class II, type V CRISPR systems
|
|
EP4121532B1
(en)
|
2020-03-17 |
2025-07-30 |
The Broad Institute, Inc. |
Crispr system high throughput diagnostic systems and methods
|
|
CN116096878A
(zh)
|
2020-05-01 |
2023-05-09 |
合成Dna技术公司 |
在非经典tttt前间区序列邻近基序处具有增强的切割活性的毛螺菌科菌种cas12a突变体
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
CN111926037A
(zh)
*
|
2020-08-27 |
2020-11-13 |
湖北省农业科学院畜牧兽医研究所 |
一种利用双sgRNA技术敲除MSTN基因的质粒及敲除MSTN基因的方法
|
|
EP4399290A4
(en)
*
|
2021-09-08 |
2025-10-01 |
Metagenomi Inc |
CLASS II TYPE V CRISPR SYSTEMS
|
|
WO2023081902A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of Florida Research Foundation, Inc. |
Systems and methods for target polynucleotide detection with crispr/cas12a using activators
|
|
AU2023246860A1
(en)
|
2022-03-30 |
2024-10-10 |
BASF Agricultural Solutions Seed US LLC |
Optimized base editors
|
|
WO2023212616A2
(en)
*
|
2022-04-27 |
2023-11-02 |
Alpha Teknova, Inc. |
Detection, quantification, and expression analysis of full viral capsids
|
|
CN119546757A
(zh)
|
2022-05-25 |
2025-02-28 |
宏基因组学公司 |
肝酶表达的补充
|
|
WO2023240061A2
(en)
*
|
2022-06-06 |
2023-12-14 |
Board Of Regents, The University Of Texas System |
Compositions and methods related to modified cas12a2 molecules
|
|
US20260071238A1
(en)
|
2022-09-02 |
2026-03-12 |
Janssen Biotech, Inc. |
Materials and processes for engineering hypoimmunogenicity
|
|
EP4638470A1
(en)
|
2022-12-21 |
2025-10-29 |
BASF Agricultural Solutions US LLC |
Increased editing efficiency by co-delivery of rnp with nucleic acid
|
|
WO2024236547A1
(en)
|
2023-05-18 |
2024-11-21 |
Inceptor Bio, Llc |
Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
|
|
WO2025007140A2
(en)
|
2023-06-30 |
2025-01-02 |
Christiana Care Gene Editing Institute, Inc. |
Nras gene knockout for treatment of cancer
|
|
WO2025046513A1
(en)
|
2023-08-29 |
2025-03-06 |
Inceptor Bio, Llc |
Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
|
|
US20250319206A1
(en)
|
2024-04-04 |
2025-10-16 |
Christina Care Gene Editing Institute, Inc. |
Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
|
|
WO2025226816A1
(en)
|
2024-04-23 |
2025-10-30 |
Christiana Care Gene Editing Institute, Inc. |
Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes
|
|
WO2026047626A1
(en)
|
2024-08-30 |
2026-03-05 |
Inceptor Bio, Llc |
Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
|